Regeneron's anti-NGF mAb meets Phase II/III endpoint

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said fasinumab ( REGN475) met the primary endpoint of significantly improving pain relief vs. placebo in a Phase II/III study to treat moderate to severe osteoarthritis (OA) pain of the hip or knee. Patients receiving 1 mg, 3 mg, 6 mg

Read the full 452 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE